Nabil Andrawis, MD
Internal Medicine · Burke, VANPI 1356310551
Payments from drug & device makers
Across 898 payments — averaging $9418.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1.6M
- Pfizer$1.3M
- Eli Lilly$1.1M
- Boehringer Ingelheim$805K
- AbbVie$719K
- Sanofi US Services Inc.$599K
- plus $2.4M from 23 others
Across 36 payments — averaging $2817.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$92K
- Sanofi US Services Inc.$4K
- Pfizer$3K
- Lexicon Pharmaceuticals, Inc.$2K
- AbbVie$923
What the payments were for
- Consulting fees$11,56082%
- Travel & lodging$1,60211%
- Food & beverage$9537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $1,555,209 |
| Pfizer | 124 | $1,312,576 |
| Eli Lilly | 28 | $1,110,113 |
| Boehringer Ingelheim | 69 | $805,361 |
| AbbVie(2 entities) | 135 | $718,790 |
| Sanofi US Services Inc. | 49 | $599,210 |
| Amgen | 6 | $317,001 |
| Genentech, Inc. | 24 | $296,174 |
| Kowa Research Institute, Inc. | 39 | $285,135 |
| Hoffmann-la Roche Limited | 13 | $280,048 |
| Bayer | 91 | $226,426 |
| Ionis Pharmaceuticals, Inc. | 20 | $174,440 |
| Novartis | 17 | $170,942 |
| Noven Pharmaceuticals, Inc. | 13 | $140,265 |
| Lexicon Pharmaceuticals, Inc. | 17 | $111,046 |
| Hikma Pharmaceuticals USA | 8 | $86,442 |
| Sanofi | 10 | $63,891 |
| Chiesi USA, Inc. | 19 | $50,116 |
| Sanofi-aventis U.S. LLC | 5 | $38,602 |
| Astrazeneca UK Limited | 2 | $37,472 |
| Boehringer Ingelheim International GmbH | 149 | $35,332 |
| Novo Nordisk AS | 1 | $18,721 |
| Shionogi Inc | 3 | $7,901 |
| Vanda Pharmaceuticals Inc. | 1 | $7,500 |
| Janssen Global Services, LLC | 3 | $3,805 |
| Novo Nordisk | 3 | $2,152 |
| Ironwood Pharmaceuticals, Inc | 1 | $1,868 |
| Abbott | 1 | $1,259 |
| Exact Sciences | 2 | $40 |
How this compares
$8,457,836 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 26 | $156 |
| Metformin Hcl | 14 | $123 |
| Lisinopril | 11 | $71 |
| Methimazole | 11 | $71 |
| Amlodipine Besylate | 17 | $52 |
| Simvastatin | 12 | $48 |
| Losartan Potassium | 11 | $43 |
| Hydrochlorothiazide | 16 | $31 |
| Atenolol | 12 | $24 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Burke
- Nashwa GabraBurke$4.3M
- Omer AbdullahBurke$248K
- Puneet NarayanBurke$49K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.